��������

Richard Parkes is a highly experienced equity analyst specializing in pharmaceuticals and biotechnology, currently serving as a Pharmaceuticals and Biotechnology Equity Analyst at Exane since July 2020. Prior to this role, Richard held significant positions at Deutsche Bank as a Director in Pharmaceuticals Equity Research and Piper Jaffray as a Senior Biotechnology Analyst. Richard began a career in finance after working as a Biotechnology Equity Analyst at ING and a Postdoctoral Research Associate at the Institute of Child Health, UCL, London. In addition to these roles, Richard contributes pro bono as a member of the Translational Scientific Advisory Committee at Proven Connect, the translational research arm of Prostate Cancer Research UK. Richard earned a Ph.D. in Molecular Genetics from the Liverpool School of Tropical Medicine between 1995 and 1999.